Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 72 of 72 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/11
End: 12/31/11
Due: 12/31/12
Phase: N/A
Priority: Normal
Start: 05/29/14
End: 02/10/17
Due: 02/10/18
Phase: N/A
Priority: Normal
Start: 02/12/21
End: 08/21/21
Due: 08/21/22
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
Phase: N/A
Priority: Normal
Start: 11/22/21
End: 12/30/25
Due: 12/30/26
Phase: N/A
Priority: Normal
Start: 07/09/20
End: 01/19/21
Due: 01/19/22
Phase: N/A
Priority: Normal
Start: 04/30/10
End: 10/31/14
Due: 10/31/15
Phase: N/A
Priority: Normal
Start: 12/27/16
End: 09/30/21
Due: 09/30/22
Phase: N/A
Priority: Normal
Start: 04/30/14
End: 11/30/15
Due: 11/30/16
Phase: N/A
Priority: Normal
Start: 09/06/21
End: 01/31/25
Due: 01/31/26
Phase: N/A
Priority: Normal
Start: 04/30/06
End: 04/30/09
Due: 04/30/10
Phase: N/A
Priority: Normal
Start: 09/18/21
End: 05/31/25
Due: 05/31/26
Phase: N/A
Priority: Normal
Start: 12/26/19
End: 02/28/23
Due: 02/28/24
Phase: N/A
Priority: Normal
Start: 07/27/21
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 10/18/17
End: 11/30/22
Due: 11/30/23
Phase: N/A
Priority: Normal
Start: 08/12/20
End: 04/24/24
Due: 04/24/25
Phase: N/A
Priority: Normal
Start: 04/02/18
End: 07/01/18
Due: 07/01/19
Phase: N/A
Priority: Normal
Start: 01/22/22
End: 08/31/25
Due: 08/31/26
Phase: N/A
Priority: Normal
Start: 07/09/20
End: 03/02/21
Due: 03/02/22
Phase: N/A
Priority: Normal
Start: 02/12/21
End: 10/11/21
Due: 10/11/22
Phase: N/A
Priority: Normal
Start: 08/19/21
End: 11/30/24
Due: 11/30/25
Phase: N/A
Priority: Normal
Start: 03/23/16
End: 02/28/17
Due: 02/28/18
Phase: N/A
Priority: Normal
Start: 08/08/17
End: 08/02/23
Due: 08/02/24